Clinio Logo
Clinio
ΔΡΑΣΤΙΚΗ ΟΥΣΙΑ A11CC01 SPC ΕΟΦ DrugBank PubChem Σκευάσματα

ERGOCALCIFEROL

For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or …

Chemical structure of ERGOCALCIFEROL

Κλινική Σύνοψη

Προτεραιότητα πηγών: SPC, ΕΟΦ, DrugBank

Curated
clinical_notes
DrugBank

Ενδείξεις

expand_more
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of…
neurology
DrugBank

Μηχανισμός δράσης

expand_more
Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is…
monitor_heart
DrugBank

Φαρμακοδυναμική

expand_more
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small…
biotech
PubChem

Φαρμακοκινητική

expand_more
Απορρόφηση, Κατανομή & Απέκκριση Η εργοκαλσιφερόλη απορροφάται στο έντερο και μεταφέρεται στο ήπαρ με χυλομικρά. Η εντερική της απορρόφηση δεν παρουσιάζει περιορισμούς, εκτός εάν υπάρχουν καταστάσεις που σχετίζονται με δυσαπορρόφηση λίπους. Ωστόσο, για…
hub
PubChem

Μεταβολισμός

expand_more
Μεταβολισμός Η εργοκαλσιφερόλη είναι ανενεργή και, ως εκ τούτου, το πρώτο βήμα στον οργανισμό καθορίζεται από τη μετατροπή αυτής της μητρικής ένωσης σε 25-υδροξυβιταμίνη D με τη δράση της CYP2R1, ακολουθούμενη από τη δημιουργία του κύριου κυκλοφορούντος…
bloodtype
PubChem

Απέκκριση

expand_more
Απορρόφηση, Κατανομή & Απέκκριση Η εργοκαλσιφερόλη απορροφάται στο έντερο και μεταφέρεται στο ήπαρ με χυλομικρά. Η εντερική της απορρόφηση δεν παρουσιάζει περιορισμούς, εκτός εάν υπάρχουν καταστάσεις που σχετίζονται με δυσαπορρόφηση λίπους. Ωστόσο, για…

Σκευάσματα & Τιμολόγηση

Δεδομένα ΕΟΦ (04/2026)
Φόρτωση...

Μονογραφίες Πηγών

Αναλυτικό περιεχόμενο ανά πηγή για τεκμηρίωση και έλεγχο

DrugBank

Description

expand_more
Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]
DrugBank

Indication

expand_more
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
DrugBank

Pharmacology

expand_more
Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D. The principal biologic function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. Cholecalciferol is synthesized within our bodies naturally, but if UV exposure is inadequate or the metabolism of cholecalciferol is abnormal, then an exogenous source is required. Vitamin D2 is converted to 25-hydroxyvitamin D (25OHD) in the liver, and then to the active form, 1,25-dihydroxyvitamin D (1,25(OH)2D), in the kidney. Once transformed, it binds to the vitamin D receptor, which leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Very few foods naturally contain vitamin D. Sources that contain the vitamin include fatty fish, the liver and fat of aquatic mammals (e.g., seals, polar bears), and eggs from chickens fed vitamin D-fortified feed. As such, many countries have instituted policies to fortify certain foods with vitamin D to compensate for the potentially low exposures of skin to sunlight. Vitamin D deficiency results in inadequate mineralization of bone or compensatory skeletal demineralization and causes decreased ionized calcium concentrations in blood and a resultant increase in the production and secretion of PTH. Increase in PTH stimulates the mobilization of skeletal calcium, inhibits renal excretion of calcium, and stimulates renal excretion of phosphorus. This results in normal fasting serum calcium concentrations and low or near-normal serum phosphorus. The enhanced mobilization of skeletal calcium induced by this secondary hyperparathyroidism leads porotic bone.
DrugBank

Mechanism of action

expand_more
Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2–5 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.
DrugBank

Absorption

expand_more
Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.
DrugBank

Half life

expand_more
19 to 48 hours (however, stored in fat deposits in body for prolonged periods).
DrugBank

Protein binding

expand_more

99.8%

DrugBank

Toxicity

expand_more
LD50 = 23.7 mg/kg (Orally in mice); LD50 = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
query_stats Κρίσιμα Στοιχεία

Ημίσεια ζωή

19 to 48 ώρες
DrugBank

Δέσμευση πρωτεϊνών

>99.8%
DrugBank

Απέκκριση

Κόπρανα
PubChem
science

Scientific Profile

CID
5280793
Μοριακός τύπος
C28H44O
Μοριακό βάρος
396.6
IUPAC
(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
InChIKey
MECHNRXZTMCUDQ-RKHKHRCZSA-N

Σχετικά Εργαλεία

Εργαλεία & Οδηγίες Όλα →
Ελλείψεις Βιταμινών διάγνωση και αναπλήρωση